Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.
Lipoxins are a novel class of endogenous eicosanoid mediators that potently inhibit inflammatory events by signaling via specific receptors expressed on phagocytic cells. Animal models have shown that lipoxin A4 (LXA4) down-regulates inflammation in vivo. Here we demonstrate, for the first time, the expression of LXA4 receptors, and their up-regulation by IL-1 beta, in normal human synovial fibroblasts (SF). We examined whether exogenous LXA4 abrogated IL-1 beta stimulation of SF in vitro. IL-1 beta induced the synthesis of IL-6, IL-8, and matrix metalloproteinases (MMP)-1 and -3. At nanomolar concentrations, LXA4 inhibited these IL-1 beta responses with reduction of IL-6 and IL-8 synthesis, by 45 +/- 7% and 75 +/- 11%, respectively, and prevented IL-1 beta-induced MMP-3 synthesis without significantly affecting MMP-1 levels. Furthermore, LXA4 induced a 2-fold increase of tissue inhibitor of metalloproteinase (TIMP)-1 and a approximately 3-fold increase of TIMP-2 protein levels. LXA4 inhibitory responses were dose dependent and were abrogated by pretreatment with LXA4 receptor antiserum. LXA4-induced changes of IL-6 and TIMP were accompanied by parallel changes in mRNA levels. These results indicate that LXA4 in activated SF inhibits the synthesis of inflammatory cytokines and MMP and stimulates TIMP production in vitro. These findings suggest that LXA4 may be involved in a negative feedback loop opposing inflammatory cytokine-induced activation of SF.
Sodin-Semrl
S
S
Section of Rheumatology, Department of Medicine, University of Illinois College of Medicine, Chicago, IL 60607, USA.
Taddeo
B
B
Tseng
D
D
Varga
J
J
Fiore
S
S
D002478:Cells, Cultured; D005347:Fibroblasts / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000378:metabolism / Q000502:physiology*; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000494:pharmacology; D007375:Interleukin-1 / Q000502:physiology*; D015850:Interleukin-6 / Q000096:biosynthesis / Q000235:genetics; D016209:Interleukin-8 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D044045:Lipoxins; D019278:Matrix Metalloproteinase 3 / Q000096:biosynthesis; D061965:Matrix Metalloproteinase Inhibitors; D012333:RNA, Messenger / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000096:biosynthesis; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin; D013583:Synovial Membrane / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000819:agonists / Q000096:biosynthesis* / Q000235:genetics; D015854:Up-Regulation / Q000276:immunology; D000093242:Interleukin-6 Inhibitors
D006893:Hydroxyeicosatetraenoic Acids; D007166:Immunosuppressive Agents; D007375:Interleukin-1; D015850:Interleukin-6; D016209:Interleukin-8; D044045:Lipoxins; D019278:Matrix Metalloproteinase 3; D061965:Matrix Metalloproteinase Inhibitors; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D044042:Receptors, Formyl Peptide; D044067:Receptors, Lipoxin; D019714:Tissue Inhibitor of Metalloproteinases; D000093242:Interleukin-6 Inhibitors; C105101:FPR2 protein, human; C040527:lipoxin A4